ContributorsPublishersAdvertisers

Bill Arthur

Neoleukin Therapeutics Announces Appointment Of Bill Arthur, Ph.D., As Vice President And Head Of Research

SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Bill Arthur, Ph.D., as Vice President and Head of Research. Dr. Arthur joins Neoleukin after a decade at Seagen, where...